TM5614联合纳武利尤单抗治疗抗PD-1抗体难治性恶性黑色素瘤的II期多中心研究
这项多中心、开放标签、单臂II期试验评估了PAI-1抑制剂TM5614联合纳武利尤单抗在抗PD-1抗体难治性不可切除黑色素瘤患者中的疗效与安全性。主要终点为联合用药8周后的总体缓解率,在27例抗PD-1抗体难治患者中为25.9%(95%CI 12.9-44.9%,P=0.027)。39例意向治疗人群中治疗相关≥3级不良事件发生率为7.7%。
要点
- TM5614联合纳武利尤单抗在抗PD-1抗体难治性黑色素瘤中8周ORR达25.9%。
- 联合方案耐受性良好,≥3级治疗相关不良事件仅7.7%。
- 抗PD-1抗体初治亚组4例患者8周缓解率为0%。
核心结论
- TM5614联合纳武利尤单抗在抗PD-1抗体难治性不可切除黑色素瘤中耐受性良好且有效。
研究设计与样本
- 多中心、开放标签、单臂II期临床试验(TM5614-MM),2021年9月13日至2023年3月31日在日本7家机构招募。
- 纳入转移性或不可切除的既往接受过抗PD-1抗体治疗的黑色素瘤患者,共39例入组,34例纳入抗PD-1抗体难治队列。
- 纳武利尤单抗480 mg每4周静脉给药共8周,TM5614口服120 mg(0-4周)和180 mg每日一次(5-8周)。
- 主要终点为联合使用TM5614 8周后的总体缓解率。
主要发现
- 方案集抗PD-1抗体难治队列27例患者8周总体缓解率为25.9%(95%CI 12.9-44.9%,P=0.027)。
- 抗PD-1抗体初治组4例患者8周缓解率为0%。
- 39例意向治疗人群中治疗相关≥3级不良事件发生3例(7.7%)。
- 7例患者因疾病进展或不良事件终止治疗。
关键数值与推荐
- 主要终点8周总体缓解率在27例经研究者评估的方案集抗PD-1抗体难治患者中为25.9%(95%CI 12.9-44.9%,P=0.027)。
- 治疗相关≥3级不良事件在39例意向治疗人群中为3例(7.7%)。
临床怎么用
- 对于抗PD-1抗体难治的不可切除黑色素瘤,可考虑TM5614联合纳武利尤单抗作为潜在治疗选择。
- 联合方案需关注治疗相关不良事件,本研究中≥3级发生率为7.7%。
局限性
- 单臂设计,无同期对照。
- 样本量较小,抗PD-1抗体初治亚组仅4例。
- 随访时间限于8周治疗期的主要终点评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-programmed cell death 1 antibodies (PD-1 Abs) are widely used for advanced melanoma, but information on the efficacy of anti-PD-1 Abs is limited in the Asian population. There remains an unmet need to improve the therapeutic effects of anti-PD-1 Ab-treatment, particularly in patients with melanoma who are refractory to anti-PD-1 Abs. The aim of this study was to evaluate anti-PD-1 Ab-treatment in combination with TM5614 (a plasminogen activator inhibitor-1 inhibitor) in patients with unresectable melanoma. METHODS: The TM5614-MM study was a multicentre, open-label, single-arm, phase II clinical trial to evaluate the efficacy and safety of nivolumab in combination with TM5614 in patients with advanced, unresectable malignant melanoma recruited at seven Japanese institutes between 13 September 2021 and 31 March 2023. Patients with metastatic or unresectable melanoma previously treated with anti-PD-1 Abs were enrolled. Nivolumab 480 mg was administered intravenously every 4 weeks for 8 weeks, while TM5614 was administered orally at a dose of 120 mg (0-4 weeks) and 180 mg once daily (5-8 weeks). The primary endpoint was the overall response rate after 8 weeks of concomitant use of TM5614. RESULTS: Thirty-nine patients were enrolled, and 34 patients were included in the anti-PD-1 Ab-refractory cohort. The overall response rate at 8 weeks was 25.9% (95% confidence interval 12.9-44.9%, P = 0.027) in 27 patients who were anti-PD-1 Ab-refractory based on investigator assessment in the protocol per set cohort. Seven patients discontinued treatment owing to progressive disease or adverse events. Treatment-related grade 3 or higher adverse events occurred in 3 of 39 patients (7.7%) in the intention-to-treat cohort. CONCLUSIONS: TM5614 in combination with nivolumab is well tolerated and effective in anti-PD-1 Ab-refractory unresectable melanoma. Types of antibody called ‘anti-programmed cell death 1 antibodies’ (also known as ‘anti-PD-1 Abs’) are commonly used to treat a range of different advanced cancers, including melanoma. However, less is known about the effectiveness of anti-PD-1 Abs, especially in Asian populations. There remains an unmet need to improve anti-PD-1 Ab-treatment, particularly in people with melanoma who are ‘refractory’ (or do not respond) to anti-PD-1 Abs in Japan. To evaluate anti-PD-1 Ab-treatment, we carried out a clinical trial called the ‘TM5614-MM study’ to investigate the safety and efficacy of using a combination of drugs (TM5614 and nivolumab). People with advanced and ‘unresectable’ (cannot be surgically removed) malignant melanoma were recruited from seven Japanese institutes between 13 September 2021 and 31 March 2023. Those with metastatic or unresectable melanoma who had received prior treatment with or without anti-PD-1 Abs were enrolled. The main result that we measured was the response rate after 8 weeks of treatment with TM5614. We found that the response rate at 8 weeks was 25.9% in 27 patients who were anti-PD-1-Ab-refractory (those who had received prior treatment with anti-PD-1 Abs) and 0% in four patients in the anti-PD-1 Ab-naïve group (those who had not previously received treatment with anti-PD-1 Abs). Treatment-related severe adverse events occurred in three of 39 patients (7.7%). Overall, our study findings suggest that TM5614 in combination with nivolumab is well tolerated and could be effective in anti-PD-1 Ab-refractory unresectable melanoma.
引用
- Fujimura T, Yoshino K, Kato H, et al. A phase II multicentre study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-programmed cell death 1 antibody-refractory malignant melanoma: TM5614-MM trial. Br J Dermatol. 2024. PMID: 38833158. doi:10.1093/bjd/ljae231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。